Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension

Research output: Contribution to journalArticlepeer-review

Standard

Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. / Yiangou, Andreas; Mitchell, James; Vijay, Vivek; Grech, Olivia; Bilton, Edward; Lavery, Gareth; Fisher, Claire ; Edwards, Julie ; Mollan, Susan; Sinclair, Alex.

In: The Journal of Headache and Pain, Vol. 21, No. 1, 116 , 25.09.2020.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Yiangou, Andreas ; Mitchell, James ; Vijay, Vivek ; Grech, Olivia ; Bilton, Edward ; Lavery, Gareth ; Fisher, Claire ; Edwards, Julie ; Mollan, Susan ; Sinclair, Alex. / Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. In: The Journal of Headache and Pain. 2020 ; Vol. 21, No. 1.

Bibtex

@article{3b30e1002e5d41e4ae9c08b324fa99ab,
title = "Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension",
abstract = "Background: Headache is the dominant factor for quality of life related disability in idiopathic intracranial hypertension (IIH) and typically has migraine-like characteristics. There are currently no evidence-based therapeutics for headache in IIH, and consequently this is an important unmet clinical need.Case series: We report a series of seven patients in whom headaches were the presenting feature of IIH and the headaches had migraine-like characteristics, as is typical in many IIH patients. Papilloedema settled (ocular remission) but headaches continued. These headaches responded markedly to erenumab, a monoclonal antibody targeted against the calcitonin gene related peptide (CGRP) receptor. Of note, there was a recurrence of raised ICP, as evidenced by a return of the papilloedema, however the headaches did not recur whilst treated with erenumab.Conclusions: Those with prior IIH who have their headaches successfully treated with CGRP therapy, should remain under close ocular surveillance (particularly when weight gain is evident) as papilloedema can re-occur in the absence of headache. These cases may suggest that CGRP could be a mechanistic driver for headache in patients with active IIH.",
keywords = "CGRP monoclonal antibody, Headache, Idiopathic intracranial hypertension, Papilloedema, Raised intracranial pressure",
author = "Andreas Yiangou and James Mitchell and Vivek Vijay and Olivia Grech and Edward Bilton and Gareth Lavery and Claire Fisher and Julie Edwards and Susan Mollan and Alex Sinclair",
year = "2020",
month = sep,
day = "25",
doi = "10.1186/s10194-020-01182-7",
language = "English",
volume = "21",
journal = "The Journal of Headache and Pain",
issn = "1129-2377",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension

AU - Yiangou, Andreas

AU - Mitchell, James

AU - Vijay, Vivek

AU - Grech, Olivia

AU - Bilton, Edward

AU - Lavery, Gareth

AU - Fisher, Claire

AU - Edwards, Julie

AU - Mollan, Susan

AU - Sinclair, Alex

PY - 2020/9/25

Y1 - 2020/9/25

N2 - Background: Headache is the dominant factor for quality of life related disability in idiopathic intracranial hypertension (IIH) and typically has migraine-like characteristics. There are currently no evidence-based therapeutics for headache in IIH, and consequently this is an important unmet clinical need.Case series: We report a series of seven patients in whom headaches were the presenting feature of IIH and the headaches had migraine-like characteristics, as is typical in many IIH patients. Papilloedema settled (ocular remission) but headaches continued. These headaches responded markedly to erenumab, a monoclonal antibody targeted against the calcitonin gene related peptide (CGRP) receptor. Of note, there was a recurrence of raised ICP, as evidenced by a return of the papilloedema, however the headaches did not recur whilst treated with erenumab.Conclusions: Those with prior IIH who have their headaches successfully treated with CGRP therapy, should remain under close ocular surveillance (particularly when weight gain is evident) as papilloedema can re-occur in the absence of headache. These cases may suggest that CGRP could be a mechanistic driver for headache in patients with active IIH.

AB - Background: Headache is the dominant factor for quality of life related disability in idiopathic intracranial hypertension (IIH) and typically has migraine-like characteristics. There are currently no evidence-based therapeutics for headache in IIH, and consequently this is an important unmet clinical need.Case series: We report a series of seven patients in whom headaches were the presenting feature of IIH and the headaches had migraine-like characteristics, as is typical in many IIH patients. Papilloedema settled (ocular remission) but headaches continued. These headaches responded markedly to erenumab, a monoclonal antibody targeted against the calcitonin gene related peptide (CGRP) receptor. Of note, there was a recurrence of raised ICP, as evidenced by a return of the papilloedema, however the headaches did not recur whilst treated with erenumab.Conclusions: Those with prior IIH who have their headaches successfully treated with CGRP therapy, should remain under close ocular surveillance (particularly when weight gain is evident) as papilloedema can re-occur in the absence of headache. These cases may suggest that CGRP could be a mechanistic driver for headache in patients with active IIH.

KW - CGRP monoclonal antibody

KW - Headache

KW - Idiopathic intracranial hypertension

KW - Papilloedema

KW - Raised intracranial pressure

UR - http://www.scopus.com/inward/record.url?scp=85092020451&partnerID=8YFLogxK

U2 - 10.1186/s10194-020-01182-7

DO - 10.1186/s10194-020-01182-7

M3 - Article

C2 - 32988380

VL - 21

JO - The Journal of Headache and Pain

JF - The Journal of Headache and Pain

SN - 1129-2377

IS - 1

M1 - 116

ER -